Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

被引：0
|
作者：
Avram Goldberg
Thomas Geppert
Elena Schiopu
Tracy Frech
Vivien Hsu
Robert W Simms
Stanford L Peng
Yihong Yao
Nairouz Elgeioushi
Linda Chang
Bing Wang
Stephen Yoo
机构：
[1] Hofstra North Shore-LIJ School of Medicine,North Shore LIJ Health Systems and Division of Rheumatology
[2] Metroplex Clinical Research Center,undefined
[3] LLC,undefined
[4] University of Michigan,undefined
[5] University of Utah,undefined
[6] RWJ Medical School Clinical Research Center,undefined
[7] Boston University School Of Medicine,undefined
[8] Benaroya Research Institute at Virginia Mason Medical Center,undefined
[9] MedImmune,undefined
[10] MedImmune,undefined
来源：
Arthritis Research & Therapy | / 16卷
关键词：
Human Papilloma Virus; Chronic Myelogenous Leukemia; Evaluable Population; Positive Baseline; Minimum Anticipate Biological Effect Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors
    Strickler, John H.
    LoRusso, Patricia
    Yen, Chia-Jui
    Lin, Chia-Chi
    Kang, Yoon-Koo
    Kaminker, Patrick
    Ansell, Peter
    Bhathena, Anahlta
    Wong, Shekman
    Dudley, Matthew W.
    Naumovski, Louie
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
    Haluska, Paul
    Menefee, Michael
    Plimack, Elizabeth R.
    Rosenberg, Jonathan
    Northfelt, Donald
    LaVallee, Theresa
    Shi, Li
    Yu, Xiang-Qing
    Burke, Patricia
    Huang, Jaiqi
    Viner, Jaye
    McDevitt, Jennifer
    LoRusso, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (18) : 4747 - 4757
  • [33] Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.
    Zhou, Fei
    Li, Wei
    Chen, Yu
    Lin, Jing
    Chen, Ling
    Zhang, Huishan
    Dong, Xiaorong
    Tong, Fan
    Zhang, Ruiguang
    Yin, Yongmei
    Liang, Yan
    Yang, Nong
    Hu, Sheng
    Zhuang, Wei
    Li, Tao
    Cai, Shengli
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer
    Kochuparambil, S. T.
    McDonald, D.
    Fidler, M.
    Stenson, K.
    Vasan, N.
    Razaq, M. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [36] A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.
    Gutierrez, Martin
    Giaccone, Giuseppe
    Harper, Harry D.
    Liu, Stephen V.
    Fang, Bruno
    Ruiz, Jimmy
    Hinson, James M.
    Orlemans, Everardus Otto
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [38] The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study
    Becker, M. O.
    Brueckner, C.
    Scherer, H. U.
    Wassermann, N.
    Humrich, J. Y.
    Hanitsch, L. G.
    Schneider, U.
    Kawald, A.
    Hanke, K.
    Burmester, G. R.
    Riemekasten, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (07) : 1340 - U186
  • [39] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
  • [40] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
12345